Transcriptional regulation of inducible nitric oxide synthase gene therapy: Targeting early stage and advanced prostate cancer

Journal of Gene Medicine

Volumn 12, Issue 9, 2010, Pages 755-765

  Coulter, Jonathan A ^a,b   Page, Natalie L ^a,b   Worthington, Jenny ^b   Robson, Tracy ^a   Hirst, David G ^a   McCarthy, Helen O ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Gene therapy; hOC; iNOS; Prostate cancer; PSMA

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ANDROGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; OSTEOCALCIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CLONOGENIC ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OSTEOCALCIN; PROSTATIC NEOPLASMS; TRANSGENES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956631775     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1495     Document Type: Article

References (57)

1. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2: 110-137.
2. O'Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998; 1443: 113-127.
3. Colombatti M, Grasso S, Porzia A, et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One 2009; 4: e4608.
4. Lee SJ, Lee K, Yang X, et al. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane- antigen. J Mol Biol 2003; 330: 749-760.
5. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124-134. (Pubitemid 43191234)
6. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995; 55: 2640-2644.
7. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998; 58: 1456-1459.
8. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230. (Pubitemid 23031827)
9. Kawakami S, Takagi K, Yonese J, Ueda T, Fukui I, Kawai T. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer. Eur Urol 1997; 32: 58-63.
10. Zhao W, Xu Y, Kong D, et al. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. Urol Oncol 2009; 27: 539-547.
11. Zhao FJ, Zhang S, Yu ZM, Xia SJ, LiH. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. Prostate Cancer Prostatic Dis 2009; 12: 166-171.
12. Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm 2009; 6: 790-800.
13. Hauschka PV, Wians FH Jr. Osteocalcin-hydroxyapatite interaction in the extracellular organic matrix of bone. Anat Rec 1989; 224: 180-188. (Pubitemid 19184417)
14. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 38: 448-452.
15. Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 1998; 23: 187-196.
16. Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-110.
17. Jung C, Ou YC, Yeung F, Frierson HF Jr, Kao C. Osteocalcin is incompletely spliced in non-osseous tissues. Gene 2001; 271: 143-150. (Pubitemid 32545391)
18. Nishimoto SK, Price PA. Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor. J Biol Chem 1980; 255: 6579-6583.
19. Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Rev 2006; 32(Suppl 1): 15-19.
20. Lipton A, Cook RJ, Coleman RE, et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007; 7: 346-353.
21. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-261. (Pubitemid 29244499)
22. Kayed H, Bekasi S, Keleg S, et al. BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Mol Cancer 2007; 6: 83.
23. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754. (Pubitemid 27516177)
24. Wai PY, Mi Z, Gao C, Guo H, Marroquin C, Kuo PC. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem 2006; 28: 18973-18982.
25. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56: 13-22.
26. Barnes GL, Javed A, Waller SM, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63: 2631-2637.
27. Shirakawa T, Ko SC, Gardner TA, et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther 1998; 5: 274-280.
28. Hinata N, Shirakawa T, Terao S, et al. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University. Int J Urol 2006; 13: 834-837.
29. Terao S, Shirakawa T, Acharya B, et al. A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy. Anticancer Res 2009; 29: 1533-1537.
30. McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. J Gene Med 2007; 9: 511-520. (Pubitemid 46993531)
31. Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 2008; 15: 495-503.
32. Shao C, Stewart V, Folkard M, Michael BD, Prise KM. Nitric oxide-mediated signaling in the bystander response of individually targeted glioma cells. Cancer Res 2003; 63: 8437-8442. (Pubitemid 37549500)
33. Shao C, Aoki M, Furusawa Y. Bystander effect in lymphoma cells vicinal to irradiated neoplastic epithelial cells: nitric oxide is involved. J Radiat Res (Tokyo) 2004; 45: 97-103.
34. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002; 277: 2468-2476.
35. Oettgen P, Kas K, Dube A, et al. Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. J Biol Chem 1999; 274: 29439-29452.
36. Noss KR, Singal R, Grimes SR. Methylation state of the prostate specificmembrane antigen (PSMA) CpG island in prostate cancer cell lines. Anticancer Res 2002; 22: 1505-1511. (Pubitemid 34839157)
37. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45: 149-157.
38. Wissenbach U, Niemeyer BA, Fixemer T, et al. Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 2001; 276: 19461-19468.
39. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539.
40. Worthington J, Robson T, Scott S, Hirst D. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Ther 2005; 12: 1417-1423. (Pubitemid 41486130)
41. Bal-Price A, Brown GC. Nitric-oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondria. J Neurochem 2000; 75: 1455-1464.
42. De Ridder M, Verellen D, Verovski V, Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008; 19: 164-169.
43. Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001; 1: 1421-1441. (Pubitemid 32622788)
44. Porasuphatana S, Tsai P, Rosen GM. The generation of free radicals by nitric oxide synthase. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134: 281-289.
45. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003; 140-141: 105-112.
46. Shacka JJ, Sahawneh MA, Gonzalez JD, Ye YZ, D'Alessandro TL, Estevez AG. Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. Cell Death Differ 2006; 13: 1506-1514.
47. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002; 12: 311-320.
48. Zou H, Li Y, Liu X, Wang X. An APAF-ytochrome c multimeric complex is a functional apoptosome that activates procaspase. Biol Chem 1999; 274: 11549-11556. (Pubitemid 129518401)
49. Messmer UK, Brune B. Nitric oxide (NO) in apoptotic vs. necrotic RAW 264.7 macrophage cell death: the role of NO-donor exposure, NAD+ content, and p53 accumulation. Arch Biochem Biophys 1996; 327: 1-10.
50. Natal C, Modol T, Oses-Prieto JA, Lopez-Moratalla N, Iraburu MJ, Lopez-Zabalza MJ. Specific protein nitration in nitric oxide-induced apoptosis of human monocytes. Apoptosis 2008; 13: 1356-1367.
51. Soler MN, Bobe P, Benihoud K, Lemaire G, Roos BA, Lausson S. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2000; 2: 344-352.
52. Chung P, Cook T, Liu K, et al. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide 2003; 8: 119-126. (Pubitemid 36287220)
53. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217-224.
54. Cook T, Wang Z, Alber S, et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 2004; 64: 8015-8021.
55. Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 2007; 167: 475-484. (Pubitemid 351292978)
56. McCarthy HO, Worthington J, Barrett E, et al. p21((WAF1))- mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14: 246-255.
57. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7: 1126-1131.